glucose lowering for cardiovascular prevention

Description Results NMA

all causes death 1.08 [0.85; 1.37]

CVdeath 1.15 [0.88; 1.51]

CV events 0.96 [0.83; 1.11]

aleglitazar 150 ìg (n=1999)

vs.

placebo (n=0)

double-blind

Parallel groups

Sample size: 1999/0

Primary endpoint: Cv events

FU duration: 58 days

aleglitazar 150 ìg daily (n=3616)

vs.

placebo (n=3610)

double-blind

Parallel groups

Sample size: 3616/3610

Primary endpoint: cardiovascular

FU duration: 2 years ( median)

all causes death 0.88 [0.71; 1.09]

CVdeath 0.85 [0.66; 1.10]

CV events 0.96 [0.83; 1.11]

alogliptin (n=2701)

vs.

placebo (n=2679)

double-blind

Parallel groups

Sample size: 2701/2679

Primary endpoint: death from cardiovascular causes, nonfatal myocardial

FU duration: 1.5 years (median)

CV events 0.86 [0.76; 0.98] Demonstrated

Hospitalization for heart failure 0.67 [0.52; 0.87]

Nephropathy 0.60 [0.47; 0.77]

amputation 1.97 [1.41; 2.75]

all causes death 0.87 [0.74; 1.02]

CVdeath 0.87 [0.72; 1.06]

fatal and non fatal stroke 0.87 [0.69; 1.09]

fatal and non fatal MI 0.89 [0.73; 1.09]

canagliflozin (n=5795)

vs.

placebo (n=4347)

double-blind

Sample size: 5795/4347

Primary endpoint: CV death, MI, stroke

FU duration: 188.2 weeks (mean)

Dapagliflozin (n=-9)

vs.

(n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration: approx 4 years (median)

CV events 0.86 [0.74; 0.99] Demonstrated

all causes death 0.68 [0.57; 0.82]

CVdeath 0.62 [0.49; 0.78]

Hospitalization for heart failure 0.65 [0.50; 0.85]

fatal and non fatal stroke 1.18 [0.89; 1.56]

fatal and non fatal MI 0.87 [0.70; 1.09]

10 mg or 25 mg of empagliflozin once daily (n=4687)

vs.

placebo (n=2333)

double-blind

Parallel groups

Sample size: 4687/2333

Primary endpoint: death from cardiovascular

FU duration: 3.1 years (median)

CV events 0.91 [0.83; 1.00] Demonstrated

all causes death 0.86 [0.77; 0.97]

CVdeath 0.88 [0.76; 1.02]

fatal and non fatal stroke 0.85 [0.70; 1.03]

fatal and non fatal MI 0.97 [0.85; 1.10]

Hospitalization for heart failure 0.94 [0.78; 1.13]

subcutaneous injections of extended-release exenatide at a dose of 2 mg once weakly (n=7356)

vs.

placebo (n=7396)

double-blind

Parallel groups

Sample size: 7356/7396

Primary endpoint: CV death, MI, stroke

FU duration: 3.2 years median

all causes death 0.98 [0.89; 1.07]

amputation 0.89 [0.60; 1.32]

CVdeath 1.00 [0.89; 1.13]

fatal and non fatal stroke 1.03 [0.88; 1.20]

fatal and non fatal MI 1.02 [0.88; 1.19]

Hospitalization for heart failure 0.90 [0.77; 1.05]

CV events 1.02 [0.94; 1.11]

Microvascular event 0.97 [0.90; 1.05]

insulin glargine (with a target fasting blood glucose level of ¡Ü95 mg per deciliter (n=6264)

vs.

standard care (n=6273)

Sample size: 6264/6273

Primary endpoint:

FU duration: 6.2 years

CV events 0.46 [0.23; 0.91]

CVdeath 1.00 [0.14; 7.14]

linagliptin (n=776)

vs.

glimepiride 1-4 mg QD (n=775)

double-blind

Sample size: 776/775

Primary endpoint: change in HbA1c

FU duration: 2 years

CV events 0.88 [0.79; 0.97] Demonstrated

all causes death 0.85 [0.75; 0.97]

CVdeath 0.79 [0.66; 0.94]

Microvascular event 0.85 [0.75; 0.98]

Nephropathy 0.80 [0.68; 0.93]

fatal and non fatal stroke 0.87 [0.71; 1.06]

fatal and non fatal MI 0.86 [0.74; 1.00]

Hospitalization for heart failure 0.88 [0.74; 1.05]

Retinopathy 1.15 [0.87; 1.52]

Maximum dose of 1.8 mg liraglutide, injected subcutaneously once daily (n=4668)

vs.

placebo (n=4672)

double-blind

Sample size: 4668/4672

Primary endpoint: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke

FU duration: 3.8 years (median)

all causes death 0.94 [0.78; 1.13]

CV events 1.02 [0.89; 1.17]

lixisenatide (n=6068)

vs.

placebo (n=0)

double-blind

Sample size: 6068/0

Primary endpoint: CVdeath, MI, stroke, or hospitalization for unstable angina

FU duration: 25 months (median)

oral pioglitazone titrated from 15 mg to 45 mg (n=2605)

vs.

placebo (n=2633)

Sample size: 2605/2633

Primary endpoint: all cause death, MI, stroke, ACS, revascularization, amputation (above ankle)

FU duration: 34.5 months

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

all causes death 1.11 [0.97; 1.28]

CVdeath 1.03 [0.87; 1.22]

fatal and non fatal stroke 1.11 [0.88; 1.40]

fatal and non fatal MI 0.95 [0.80; 1.12]

CV events 1.00 [0.89; 1.12]

saxagliptin (n=8280)

vs.

placebo (n=8212)

double-blind

Parallel groups

Sample size: 8280/8212

Primary endpoint: cardiovascular death, myocardial infarction, or ischemic stroke

FU duration: 2.1 years (median)

CV events 0.74 [0.58; 0.95] Demonstrated

Nephropathy 0.64 [0.46; 0.89]

Retinopathy 1.76 [1.11; 2.79]

all causes death 1.05 [0.74; 1.49]

CVdeath 0.98 [0.65; 1.48]

once-weekly semaglutide (0.5 mg or 1.0 mg) (n=1648)

vs.

placebo (n=1649)

double-blind

Parallel groups

Sample size: 1648/1649

Primary endpoint: CV death, MI or stroke

FU duration: 2.1 y (median)

all causes death 1.01 [0.90; 1.14]

CVdeath 1.03 [0.89; 1.19]

fatal and non fatal stroke 0.97 [0.79; 1.19]

fatal and non fatal MI 0.95 [0.81; 1.11]

CV events 0.99 [0.89; 1.10]

sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily (n=7332)

vs.

placebo (n=7339)

double-blind

Parallel groups

Sample size: 7332/7339

Primary endpoint: CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization

FU duration: 3.0 years (median)